Akero Therapeutics Inc - AKRO Net Assets per Single Share

Graphic logo of Akero Therapeutics (AKRO)

Akero Therapeutics (AKRO) aims to capture the premium market segment by developing unique treatments for liver pathologies, which will provide the company with significant pricing power. This business remains independent of economic cycles and seasonality, relying solely on medical trial results. The current price action, where the indicator stands at 11.99, is presented below. Akero Therapeutics (AKRO) is building its own network of partnerships with hepatologists to implement new therapy standards.

Akero Therapeutics, Inc. (AKRO): Share Book Value from 07/04/2022 to 12/20/2025

akerotx.com - analytical breakdowns and key metrics (AKRO)

- price and consensus price forecast:
Price Chart Akero Therapeutics Inc|AKRO - Fair Value Consensus
- market capitalization data:
Market Value Akero|AKRO - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Akero Therapeutics|AKRO - Net Asset Value|Market Capitalization to Book Value Ratio akerotx.com|AKRO - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Akero Therapeutics|AKRO - Long-Term Debt to Capital|Short-Term Debt to Equity Akero|AKRO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Akero|AKRO - Company Long-Term Liabilities|Company Short-Term Debts Akero Therapeutics
Fundamental company valuation:Akero Therapeutics Inc - AKRO
Manufactured products of Akero

Akero Therapeutics (AKRO) operates as a biotech startup whose financial potential is based on attracting investment rather than commercial sales. The book value per share is calculated as the difference between all assets and liabilities, divided by the number of shares. This metric determines the actual value of capital available to the shareholder upon business liquidation. It is critical for investors to compare this figure with the market price to identify undervaluation. By analyzing this book value per share chart, one can track the dynamics of the company's net capital.

Competitors of Akero Therapeutics (AKRO)

Net Assets per Single Share Ascendis Pharma Inc. (ASND)|MDGL: Accounting Value of a Share|Net Assets per Single Share CORT|RYTM (rhythmtx.com) - Net Asset Value per Share|Net Assets per Single Share Metsera MTSR|Share Book Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Book Value per Share|Accounting Value of a Share NewAmsterdam Pharma Corp (NAMS)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS